Our journey with cachexia was a challenging two-year battle. In 2019, my father was diagnosed with Myelodysplasia, a rare blood cancer, which was exacerbated by cachexia, and in the spring of 2022, he lost his fight against this life-threatening disease. Cachexia, a condition with no FDA-approved treatments, is often experienced by cancer patients, leading to decreased appetite and unintended weight loss, impacting their ability to tolerate treatment.
The timelapse captured by the two pictures below symbolizes the rapid progression of cachexia within a short span of two years, highlighting the urgency to address this critical issue. At Pfizer, we look at understanding how GDF-15, a protein associated with cachexia may impact outcomes for individuals battling cancer.
Together, we strive to deepen our understanding of cachexia and its complexities, aiming to pave the way for innovative solutions and improved outcomes for those affected by this life-threatening condition. Learn more about our approach https://lnkd.in/e2vPr6JP #CachexiaAwareness #InnovativeResearch #PfizerCares
Biotech CEO, Advisor and Board Member
1moCongratulations, Marianne D. De Backer, MSc, PhD, MBA and Vir Biotechnology, Inc. team!